U.S. Markets open in 7 hrs 22 mins

Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks

Stock Research Monitor: DARE, DRNA, and EGLT

LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on DERM sign up now at www.wallstequities.com/registration. On Friday, the NASDAQ Composite ended the day at 7,746.38, down 0.19%; the Dow Jones Industrial Average edged 0.34% lower, to finish at 25,090.48; and the S&P 500 closed at 2,779.66, marginally slipping 0.10%. US markets saw five out of nine sectors finishing the day in green and four in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Daré Bioscience Inc. (NASDAQ: DARE), Dermira Inc. (NASDAQ: DERM), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA), and Egalet Corp. (NASDAQ: EGLT). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Daré Bioscience

La Jolla, California headquartered Daré Bioscience Inc.'s stock finished Friday's session 1.45% lower at $1.36 with a total trading volume of 263.030 shares. The stock has gained 23.64% in the past month and 33.33% over the past three months. The Company's shares are trading above their 50-day moving average by 24.04%. Moreover, shares of Daré Bioscience, which focuses on developing and marketing women's reproductive health products in the US, have a Relative Strength Index (RSI) of 60.73. Get the full research report on DARE for free by clicking below at:

www.wallstequities.com/registration/?symbol=DARE

Dermira

Shares in Menlo Park, California headquartered Dermira Inc. rose 0.20%, ending last Friday's session at $10.02 with a total trading volume of 1.74 million shares, which was higher than their three months average volume of 929.13 thousand shares. The stock has gained 10.11% in the previous three months. The Company's shares are trading above their 50-day moving average by 8.07%. Moreover, shares of Dermira, which identifies, develops, and commercializes therapies to treat dermatologic diseases, have an RSI of 57.97. The free technical report on DERM can be accessed at:


www.wallstequities.com/registration/?symbol=DERM


Dicerna Pharmaceuticals

On Friday, Cambridge, Massachusetts headquartered Dicerna Pharmaceuticals Inc.'s stock saw a drop of 0.86%, to close the day at $12.74. A total volume of 450,038 shares was traded. The Company's shares have advanced 337.80% over the last twelve months. The stock is trading above its 200-day moving average by 35.53%. Additionally, shares of Dicerna Pharma, which focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infections, chronic liver, and cardiovascular diseases, have an RSI of 44.90. Sign up for free on Wall St. Equities and claim the latest report on DRNA at:

www.wallstequities.com/registration/?symbol=DRNA

Egalet

Shares in Wayne, Pennsylvania headquartered Egalet Corp. ended the day flat at $0.47. A total volume of 273,349 shares was traded. The Company's shares are trading below their 50-day moving average by 18.28%. Furthermore, shares of Egalet, which develops, manufactures, and commercializes treatments for patients with pain and other conditions, have an RSI of 42.17. See the free research coverage on EGLT at:

www.wallstequities.com/registration/?symbol=EGLT

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities